NYSE · NVST
Envista Holdings Corp
Healthcare · Medical - Instruments & Supplies
$23.60▼ 1.54% ($0.37)at close
As of 4:00 PM ET
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 3.7% a year for 10 years. Our scenarios assume 1.4–4.4%.
That's below its past 4-year pace of 2.0%.
Value per share
Base case
$38.15
Price used $23.60 is 38% below this
USD · TTM ending Jul 3, 2026 · Price Oct 23, 8:00 PM UTC
Revenue each value needs
Revenue today $2.9B. The price needs $2B by 2036. Base case: $3.5B. At its recent pace: $3.5B. Bear to Bull: $3.3B to $4.4B.
Revenue today $2.9B. The price needs $2B by 2036. Base case: $3.5B. At its recent pace: $3.5B. Bear to Bull: $3.3B to $4.4B.
Revenue in 2036
today $2.9B
−$1.5Bless than the Base case
Value per share · Base case
$38.15
Price $23.60
38% below this
- 10-yr revenue CAGR
- 1.9%
- Ending operating margin
- 9.9%
- Discount rate
- 6.9%
USD · TTM ending Jul 3, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 16.72% over the last year. Revenue grew 11.89% over the trailing twelve months. Operating margin moved from 6.14% to 9.92%. Free cash flow declined 9.93% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 39th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 9.92%. Revenue grew 11.89% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 9.93%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
8
Buy
11
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $0.36 · Revenue est $688.8M
Same quarter, year over year
FY26 YTD +54.0%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $0.77 vs $0.50 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $1.20
- +64.4%
- FY24
- $0.73
- —
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.41
Estimate
$0.34
Year over year
+57.7%
Vs prior quarter
+13.9%
Institutional Sentiment
Envista Holdings Corp · NVST
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.